Deciphering the role of malin in the Lafora progressive myoclonus epilepsy by Romá-Mateo, Carlos et al.
1 
 
Deciphering the role of malin in the Lafora progressive myoclonus epilepsy. 
 
Carlos Romá-Mateo1, Pascual Sanz1 *#, and Matthew S. Gentry2*# 
 
1 Instituto de Biomedicina de Valencia, CSIC and Centro de Investigación Biomédica en 
Red de Enfermedades Raras (CIBERER), Jaime Roig 11, 46010-Valencia, Spain. 
2 Department of Molecular and Cellular Biochemistry and Center for Structural Biology, 
University of Kentucky, Lexington, KY 40536-0509, USA. 
 
* These co-senior authors contributed equally to this work 
 
# Corresponding authors: Dr. Pascual Sanz, Instituto de Biomedicina de Valencia, CSIC 
and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Jaime 
Roig 11, 46010-Valencia, Spain. Tel. +34963391779; FAX: +34963690800; email: 
sanz@ibv.csic.es; Dr. Matthew S. Gentry, Department of Molecular and Cellular 
Biochemistry and Center for Structural Biology, University of Kentucky, Lexington, KY, 
USA, Tel. +1-8593238482, FAX. +1-8593235505, E-Mail: matthew.gentry@uky.edu 
 
Keywords: Laforin, malin, glucan phosphatase, Lafora disease, Lafora bodies, glycogen, 
autophagy, ER stress, Ubiquitination, E3-ubiquitin ligase. 
 
ABSTRACT 
Lafora disease (LD) is a fatal, autosomal recessive neurodegenerative disorder that results 
in progressive myoclonus epilepsy. A hallmark of LD is the accumulation of insoluble, 
aberrant glycogen-like structures called Lafora bodies. LD is caused by mutations in the 
gene encoding the E3 ubiquitin ligase malin or the glucan phosphatase laforin. Although 
LD was first described in 1911, its symptoms are still lacking a consistent molecular 
explanation and consequently a cure is far from being achieved. Some data suggest that 
malin forms a functional complex with laforin. This complex promotes the ubiquitination 
of proteins involved in glycogen metabolism and misregulation of pathways involved in 
this process results in Lafora body formation. In addition, recent results obtained from both 
cell culture and LD mouse models have highlighted a role of the laforin-malin complex in 
the regulation of ER-stress and protein clearance pathways. These results suggest that LD 
should be considered as a novel member of the group of protein clearance diseases such as 
Parkinson’s, Huntington’s, or Alzheimer’s, in addition to being a glycogen metabolism 
disease. Herein, we review the latest results concerning the role of malin in LD and attempt 
to decipher its function. 
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INTRODUCTION 
 Lafora progressive myoclonus epilepsy (Lafora disease, LD; OMIM 254780) is a 
rare, fatal neurodegenerative disorder characterized by epilepsy, neurodegeneration and 
accumulation of polyglucosan inclusions in brain and other peripheral tissues [1]. It was 
described in 1911 by the Spanish neurologist Gonzalo R. Lafora, who described the 
presence of dark and intense inclusions in post-mortem preparations of patients that he 
called “amyloid bodies” [2]. While amyloid was later shown to be proteinaceous, the term 
originally referred to material that stained similar to plant starch [3]. The “amyloid bodies” 
of LD were shown to be water-insoluble glucans that are in fact very similar to plant starch 
and were named Lafora bodies (LBs) ([4], [5]). LD manifests during adolescence with 
generalized tonic-clonic seizures, myoclonus, absences, drop attacks and visual 
hallucinations. A progressive dementia with apraxia, aphasia and visual loss follows, 
leading patients to a vegetative state and death, usually within the first decade from the 
onset of the disease ([6], [7], [8]). 
 LD-causing mutations have been identified in two genes, EPM2A, encoding the 
glucan phosphatase laforin, and EPM2B/NHLRC1, encoding the E3 ubiquitin ligase malin 
([9], [10], [11]). The identification of the malin and laforin genes and determining their 
biochemical activities were key steps in unraveling the cellular mechanisms that cause LD; 
however, there was not an obvious link between the phosphatase laforin and the E3 ligase 
malin. An emerging theme came from multiple labs showing that malin ubiquitinates 
substrates in a laforin-dependent manner, suggesting that malin and laforin form a 
functional complex ([12], [13], [14], [15]). These biochemical results are consistent with 
LD clinical data: patients carrying mutations in either EPM2A or EPM2B are 
phenotypically indistinguishable. Therefore, laforin and malin likely function in the same 
physiological pathway. 
 In the last decade, several laboratories have described possible functions of laforin 
and malin in cell physiology. While incomplete, these data are beginning to elucidate the 
molecular bases of the pathophysiology of LD. These results suggest that LD has strong 
similarities with more frequent neurological disorders like Parkinson’s, Huntington’s, and 
Alzheimer’s. In this review we discuss the current knowledge of the E3 ubiquitin ligase 
malin in Lafora disease. 
 
1.- E3-ubiquitin ligase activity of malin. 
 In 2003, Minassian and colleagues [11] described that mutations in EPM2B result in 
LD. EPM2B is located in chromosome 6q22.3 and contains a single exon encoding a 395 
amino acid protein named malin. Malin is an E3-ubiquitin ligase with a zinc finger RING 
(Really Interesting New Gene) domain of the C3HC4 type at the N-terminus and six NHL 
domains (also present in NCL1, HT2A and LIN-41 proteins) at the C-terminus. The NHL 
domains are predicted to fold into a -propeller structure that mediates protein-protein 
interactions (Fig. 1). 
 Ubiquitination is one of the most common post-translational modifications of 
proteins. It occurs by the addition of ubiquitin monomers to a lysine of a target protein by a 
process involving three different steps: 1) activation of ubiquitin by the E1-ubiquitin 
activating enzyme; 2) transfer of the activated ubiquitin to the E2-ubiquitin conjugating 
enzyme; and 3) attachment of ubiquitin to a lysine of the substrate either directly via a 
HECT-type E3 ligase or indirectly in the case of RING-type E3 ligases ([16], [17]). The 
reaction results in the attachment of a single ubiquitin moiety to one lysine 
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(monoubiquitination), a single ubiquitin to several lysines (multiubiquitination), or several 
ubiquitin molecules to one lysine (polyubiquitination). In the latter case, new ubiquitin 
molecules are linked to previous moieties using any of the seven internal lysine residues 
present in ubiquitin (K6, K11, K27, K29, K33, K48, and K63). Depending on the type of 
linkage present in the polyubiquitin chain, the substrate is targeted to the proteasome for 
destruction (K48-linked chains) or the modification  causes  changes in cell signalling, 
trafficking, and/or interactions with other proteins ([16], [17], [18]). 
 As indicated above, malin is a RING-type E3-ubiquitin ligase. Among the 38 E2-
conjugating enzymes encoded in the human genome, malin is able to interact in vitro with 
UbcH2, UbcH5a, UbcH5c and UbcH6 and not with UbcH1, UbcH3, UbcH5b, UbcH7, 
UbcH10 and UbcH13 [12]. However, the E2s that participate in the in vivo ubiquitination 
process mediated by malin are still unknown. Identification of the endogenous E2(s) is an 
important point to be resolved since the topology of the polyubiquitin chains present in a 
substrate depends both on the type of the E2s and the E3s ([16], [17]). We and others have 
reported that malin mediates the incorporation of both K48- and K63-linked ubiquitin 
chains in different substrates, but it is unknown which E2(s) participates in these events 
([12], [19], [20], see below).  
 
2.- Mutations in EPM2B 
 Approximately 60 different mutations in the EPM2B have been associated with LD 
to date [21]. Some of these mutations affect the enzymatic activity of malin, whereas others 
affect the interaction between malin and another protein. The most prevalent mutation is 
P69A, in the RING motif of malin. The malin-D146N mutation disrupts the interaction 
with laforin without altering the ubiquitinating activity of malin [15] (Fig. 1). This mutation 
impairs the formation of a functional laforin-malin complex ([14], [15]) and leads to 
aberrant glycogen accumulation [22]. Although patients with mutations in laforin or malin 
show similar clinical manifestations, those carrying mutations in the EPM2B have a less 
severe progression of the disease and live longer. In fact, the mutation D146N has been 
associated with a slower progression of the disease ([23], [24], [25]). 
 
3.- Malin phylogeny. 
 From an evolutionary point of view, the fact that malin forms a functional complex 
with laforin raised the question of whether these two proteins share a common phylogenetic 
lineage or whether they evolved independently. Laforin is conserved in all vertebrates, a 
select group of protozoans, and in two invertebrate genomes; however, the gene encoding 
laforin is absent from most protozoan and invertebrate genomes such as yeast, fly and 
worm ([26], [27]). A recent study investigated malin phylogeny and found that the malin 
gene is exclusively found in vertebrate genomes and the cephalochordate Branchiostoma 
floridae [28]. Thus, the distribution of malin does not correlate with that of laforin, 
suggesting that laforin has a malin-independent function(s) [28]. This study also reported 
an evolutionary relationship between malin and TRIM32, an E3-ubiquitin ligase that 
belongs to the TRIM family (TRIpartite Motif-containing). Both malin and TRIM32 
exhibit a similar modular structure, containing a functional RING motif and six NHL-
protein interaction motifs. Species distribution of malin and TRIM32 and the exon-intron 
composition of both proteins further corroborated the possibility of a common phylogenetic 
origin. Moreover, some functional redundancies were also discovered: TRIM32 is capable 
of ubiquitinating some malin substrates in overexpression cell culture systems, but with 
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different polyubiquitin chain topology. However, this redundancy was not reciprocal since 
specific TRIM32 substrates were not ubiquitinated by the laforin-malin complex. 
Cumulatively, the phylogenetic studies suggest that malin initially evolved from ancestral 
TRIM genes and developed a particular E3 ubiquitin ligase activity, possibly co-evolving 
with laforin as a binding partner in vertebrate species [28]. 
 
4.- Subcellular localization of malin 
 Attempts to define the subcellular localization of endogenous malin have been 
unsuccessful due to the lack of a reliable α-malin antibody. Ganesh and co-workers, using 
overexpression studies of malin fused to GFP indicated that malin is located at the 
endoplasmic reticulum and that upon treatment of the cells with the proteasome inhibitor 
MG132, malin forms perinuclear aggregates that are also immunoreactive against ubiquitin, 
ubiquitin-conjugating enzymes, chaperones and proteasome subunits [29]. The same group 
showed later that malin predominantly localizes to the nucleus and this localization does 
not change upon subjecting the cells to heat shock or glucose starvation ([30], [31]).  Cheng 
et al. reported that low-level expression of malin-myc localizes to the nucleus and gross 
overexpression results in malin-myc perinuclear ER-like localization [32]. Although these 
studies offer insights into malin function, there have been no reports to date that 
demonstrate endogenous malin localization. 
 
5.- Malin interacting partners and physiological pathways involved. 
5.1.- Laforin 
As mentioned above, laforin and malin form a functional complex and are likely 
involved in the regulation of multiple pathways. The first indication that malin interacted 
with laforin came from yeast two-hybrid experiments ([12], [13, 32], [33]). The 
physiological relevance of this interaction is highlighted by the fact that the Lafora disease 
mutation malin-D146N abolishes the malin-laforin interaction without affecting the E3-
ubiquitin ligase activity of malin [15]. The malin-laforin interaction was confirmed by co-
immunoprecipitation of the two proteins, and the interaction was shown to be direct using 
purified recombinant proteins [12]. Moreover, work from Guinovart and colleagues 
elegantly reported a mechanism whereby the malin-laforin complex inhibits neuronal 
glycogen synthesis [14]. Despite these convincing studies, the lack of an α-malin antibody 
has impeded the confirmation of the malin-laforin complex in a truly physiological context. 
Laforin and malin exhibit an intriguing relationship because while they form a 
complex, malin also ubiquitinates laforin and targets it for degradation [12]. Malin-directed 
degradation of laforin is counter-intuitive since loss of either gene results in LD.  However, 
patient mutations in malin result in increased levels of laforin [11], and similar results are 
observed in malin-deficient mouse models [11]([34], [35], [36], [37]). While we and others 
interpret these results to mean that malin promotes the degradation of laforin, others in the 
field disagree (see below). An additional layer of complexity arises from the fact that one 
group reported that malin is more abundant in the presence of laforin [14]. These results 
suggest that laforin increases the stability of malin in spite of laforin being degraded by 
malin (Fig. 2). 
We reported that the interaction between laforin and malin is enhanced by the AMP-
activated protein kinase (AMPK) [15]. AMPK phosphorylates laforin at residue Ser25 and 
this modification increases the interaction between laforin and malin [38]. Conditions that 
trigger the activation of AMPK such as glucose starvation, improve the interaction between 
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laforin and malin ([15], [31]). These results predict that AMPK activation would lead to 
lower levels of R5/PTG and glycogen synthase, known substrates of the laforin-malin 
complex. However, DePaoli-Roach et al  found no change in R5/PTG levels in mice under 
conditions that activate AMPK [34]. Thus, more work is required to define more precisely 
the role of AMPK in laforin-malin regulation.  
 
5.2.- Enzymes involved in glycogen synthesis. 
 One of the first identified substrates of the laforin-malin complex was R5/PTG 
([14], [15], [39]). R5/PTG, encoded by PPP1R3C gene, is a targeting subunit of protein 
phosphatase 1 (PP1), directing PP1 to glycogen. R5/PTG-targeted PP1 dephosphorylates 
glycogen synthase, activating it, and thus is an activator of glycogen synthesis.  R5/PTG-
directed PP1 also dephosphorylates and inhibits glycogen phosphorylase. Therefore, 
misregulation of R5/PTG affects both synthesis and breakdown of glycogen ([40], [41], 
[42]). Results from three labs demonstrated that the laforin-malin complex ubiquitinates 
R5/PTG, decreases R5/PTG protein levels, and downregulates glycogen levels. The laforin-
malin complex also interacts  with the PP1 binding partners GL (PPP1R3B) and R6 
(PPP1R3D), but not GM (PPP1R3A) ([39], [43]). In addition to affecting PP1 activity, the 
laforin-malin complex ubiquitinates and downregulates the activity of glycogen synthase 
(GS) [14] and glycogen debranching enzyme (GDE/AGL) [32]. Jana and colleagues 
recently reported that the laforin-malin complex controls glycogen synthesis by 
ubiquitinating and promoting the proteasomal degradation of neuronatin, an 81 amino acid 
protein that stimulates glycogenesis [44]. These reports strongly suggest a role for the 
laforin-malin complex in the regulation of glycogen synthesis. For this reason, it was 
proposed that in the absence of a functional laforin-malin complex glycogen synthesis 
would proceed without proper coordination and would result in the accumulation of poorly 
branched polyglucosan species, i.e. Lafora bodies (Fig. 2), (Fig. 3). 
 Although the above work is from multiple labs using different systems, these results 
are largely based on overexpression of laforin and malin in cell cultures and on in vitro 
results utilizing recombinant proteins. In contrast to these results, mice lacking either malin 
or laforin that are 3 to 6 months of age do not show increased levels of glycogen synthase 
or R5/PTG ([34],  [35], [45]). However, a more recent report on this matter indicates that in 
the brain of 11 month old mice lacking malin, there is an increase in the levels of glycogen 
synthase [36], suggesting that the laforin-malin complex does downregulate the levels of 
proteins involved in glycogen synthesis. Obviously, more work is needed to reconcile these 
results (Fig. 3). 
 
5.3.- Malin in ER-stress and protein clearance. 
 In addition to the role that the laforin-malin complex has in glycogen homeostasis, 
the complex has additional roles in several other pathways. Multiple labs have reported that 
the laforin-malin complex plays a role in protecting cells from ER-stress conditions ([46], 
[47]). In cell culture models depleted of malin or laforin there is increased ER-stress 
response that eventually leads to decreased proteasome function and increased apoptosis, 
which could be important factors in the development of LD ([46], [47]) (Fig. 2). 
It has also been reported that laforin and malin form a functional complex with 
Hsp70 and that this macro-complex suppresses the cytotoxicity produced by the 
accumulation of misfolded proteins (i.e., expanded polyglutamine proteins, and -
synuclein) [48]. It was proposed that laforin interacts with both Hsp70 and misfolded 
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proteins while recruiting malin to trigger the ubiquitination of these proteins and targeting 
them for degradation. These results suggest that the laforin-malin complex could be 
considered as a new component of the neuronal response to misfolded proteins.  If correct, 
the laforin-malin complex could have similar functions in protein clearance as those 
reported for other E3-ubiquitin ligases such as parkin, CHIP, dorfin and E6-AP [48]. Given 
these results, it has been proposed that one of the primary causes of Lafora disease may be 
the inability to eliminate misfolded proteins, and for this reason, the disease should be 
considered as a novel member of the group of protein clearance diseases ([8], [29]) (Fig. 2). 
Additionally, it was recently described that the laforin-malin complex is a positive 
regulator of autophagy. Cellular and mouse models lacking either laforin or malin show a 
decrease in autophagy, likely due to an impairment in autophagosome formation ([37], 
[49]). In both cases, there are decreased content of autophagic vesicles and lower levels of 
the LC3-II autophagic marker. As a result of autophagic dysfunction, there are increased 
levels of the p62 autophagic marker in both cases. The autophagic dysfunction observed in 
models lacking either laforin or malin may lead to the accumulation of diverse autophagic 
substrates that would contribute to cell stress and cell death. Rodriguez de Cordoba and 
colleagues recently reported autophagy defects in 16-day-old mice lacking malin [37]. 
Therefore, these defects may occur at a very early stage of the disease and these results 
further highlight the similarities to other more common neurological disorders that present 
similar autophagic impairment like Parkinson’s, Alzheimer’s or Huntington’s [50] (Fig. 2). 
Thus, a common reoccurring theme is the similarities between Lafora disease and these 
disorders. 
 
5.4.- Malin and transcriptional regulation. 
Two reports recently implicate malin in transcriptional regulation. One group 
demonstrated that laforin and malin form a ternary complex with the co-chaperone CHIP 
(C-terminus Hsp70 Interacting Protein). This interaction improved the stability of malin 
[51] and was necessary for the heat shock response mediated by the transcription factor 
HSF1 (Heat Shock Factor 1) [30]. These authors reported that laforin translocates to the 
nucleus after heat shock, requiring both CHIP and HSF1 for this nuclear translocation. 
Once inside the nucleus, the laforin-malin complex is required for the function of HSF1 as 
a transcriptional regulator. These results indicate that the laforin-malin complex is required 
for full protection against heat-shock-induced cell death and provide another link between 
laforin-malin and cellular responses to stress [30] (Fig. 2).  
 In the second report, malin was shown to interact with dishevelled2 (Dvl2), a key 
component of the Wnt signalling pathway. Dvl2 is a cytosolic protein that regulates -
catenin shuttling to the nucleus where -catenin mediates transcription of Wnt target genes. 
The authors reported that malin enhances K48- and K63-linked ubiquitination of Dvl2, 
promotes its degradation via the proteasome and autophagy, and inhibits Wnt signalling. 
These results suggest a possible dysregulation of Wnt signalling in Lafora disease [20]. 
Loss of function of malin may increase Wnt signalling in developing or adult brain leading 
to abnormal synaptic differentiation, synaptic plasticity, or other neurogenic defects (Fig. 
2). 
 
6.- Animal models lacking malin 
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 Multiple animal models lacking malin have been utilized to study LD. The first 
animal model of Lafora disease due to mutations in EPM2B was that of miniature 
wirehaired dachshunds. LD is caused in these dogs by the expansion of a 12-nucleotide 
sequence in the region between the RING finger and the NHL domains. This expansion, 
containing from 14 to 26 repetitions, severely decreases malin mRNA levels (900 times 
lower than wild type) [52]. The expansion was found in many Canidae species, but not in 
closely related Arctoidae or Felidae and was only commonly found in miniature wirehaired 
dachshunds. Although these dogs provided valuable insights into LD, the difficulty in their 
handling and breeding does not make them an appropriate model to study the mechanistic 
cause of human LD. 
 In addition to the canine model, multiple mouse models lacking Epm2b have been 
generated. DePaoli-Roach et al.,  analyzed 3-month-old mice lacking Epm2b  and reported 
that these mice develop Lafora bodies in brain, heart, and skeletal muscle [34]. 
Additionally, they observed no increase in glycogen synthase, R5/PTG, or glycogen 
debranching enzyme in these animals and they did not observe any changes in enzymatic 
activities of glycogen metabolism enzymes; specifically, glycogen synthase and glycogen 
phosphorylase enzymatic activities were unchanged. However, they did observe increases 
in laforin protein levels.  They reported that laforin from wild-type animals was found in 
the soluble fraction after a low-speed spin, but the increased laforin protein in Epm2b-/- 
mice was observed in a low speed insoluble pellet. They proposed that the absence of malin 
promotes the accumulation of LBs by an unknown mechanism and that LBs sequester 
laforin and protect it from degradation by another source than malin-directed degradation. 
Thus, they argued that the increase in laforin occurs indirectly in malin deficient mice and 
not because malin is the E3 ligase for laforin. However, as described above, we previously 
reported that malin ubiquitinates and promotes the degradation of laforin in cell culture and 
recapitulated these results using purified recombinant proteins in vitro [12]. 
 Shortly after the first report, Minassian and colleagues published a second mouse 
model lacking Epm2b  [35]. They analyzed 6-month-old animals and they also reported that 
the mice develop LBs in brain, skeletal muscle, and liver, indicating that the mouse model 
recapitulates the disease. They too reported that glycogen synthase levels and activity are 
unchanged in mice lacking Epm2b.  Similar to DePaoli-Roach et al., they reported higher 
levels of laforin in their mice and an increase of laforin in the insoluble fraction, but they 
did not observe a decrease of laforin in the soluble fraction. Thus, they did not observe a 
redistribution of laforin, but did observe increased laforin in the insoluble pellet.  They too 
argue that the increase in laforin in malin-deficient mice is a result of laforin being 
“trapped” in LBs.  Thus, they argue that malin does not regulate the protein levels of 
laforin, but that laforin levels are increased in malin-deficient mice by the indirect 
accumulation of laforin in LBs.  Additionally, they reported that malin-deficient mice have 
increased levels of glycogen phosphate as compared to wild-type animals, but not as high 
as in laforin-deficient mice. The authors hypothesize that lack of malin results in LB 
formation only in part due to increased glycogen phosphorylation, and that malin has an 
additional function in regulating glycogen metabolism that contributes to LD.  
 At a later date, Guinovart and colleagues reported their results from the analysis of 
11-month-old Epm2b-/- mice [36].  They confirmed the presence of LBs reported by the 
earlier groups, but extended these findings with elegant microscopy focused on the 
hippocampus. They found LBs in both neurons and astrocytes.  Importantly, they reported 
that LBs in soma and processes of parvalbumin-positive interneurons were accompanied by 
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progressive loss of these neurons and neurophysiological alterations, providing a direct link 
between LBs and impairment of hippocampal function.  Additionally, they found increased 
levels of glycogen synthase in 11-month-old malin-deficient mice, but did not observe 
increases in glycogen synthase activity. [36]. This report suggests that the age of the mice 
studied may explain the differences in reported results. 
Recently, a fourth mouse model lacking Epm2b was reported by Rodriguez de 
Cordoba and colleagues [37]Phenotypically, at six months of age, these mice were similar 
to those reported above: they accumulate LBs in different areas of the brain and they 
exhibit higher levels of laforin. This group extended our understanding of LD by analyzing 
young, 16-day-old Epm2b-/- mice.  They found that in 16-day-old malin-deficient mice 
there are no visible LBs present in brain, yet laforin levels are increased and the increased 
laforin is found in the soluble fraction. As the mice aged, LBs appeared and laforin became 
enriched in the insoluble fraction, possibly forming part of these LBs.  The authors then 
investigated autophagy in this model and reported that Epm2b-/- mice exhibit a dysfunction 
in autophagy in animals as young as 16 days old.  Therefore they concluded that autophagy 
is one of the first determinants that is impaired in Lafora disease. In addition, these authors 
reported neurological and behavioural abnormalities in Epm2b-/- mice, such as reduced 
spontaneous motor activity and coordination, abnormal clasping upon tail suspension and 
reduced object recognition task [37]. 
In conclusion, several animal models of LD caused by the lack of malin are now 
available. These animals recapitulate most of the features present in LD patients, thus they 
are good models to study the pathophysiology of the disease.  The initial reports utilizing 
these models have observed some differences, but future studies will likely result in a 
unifying theme describing how the loss of malin results in LBs and Lafora disease.   
 
7.- PERSPECTIVES 
Greater than 100 papers have been published on Lafora disease in the last five years. 
In spite of the advances during this time, there are still holes in our understanding of the 
cellular basis of the disease and controversies that need to be resolved. For example, what 
is the role of malin in the regulation of glycogen synthesis? Pioneering work by the Dixon 
and Roach labs established that laforin is a glucan phosphatase, that acts as a control 
mechanism to eliminate the phosphates that glycogen synthase introduces erroneously into 
the glycogen molecule ([26], [53], [54], [55]). Thus, there is a direct path where loss of 
laforin leads to hyperphosphorylation of glycogen that eventually turns into a Lafora body 
causing LD. 
Similar hyperphosphorylated glycogen is observed in mouse models lacking malin; 
however, these animals also contain higher levels of laforin.  Therefore, these results are 
difficult to reconcile.  As discussed above, there is no consensus as to whether or not malin 
regulates protein levels of glycogen metabolism enzymes. Thus, the mechanism for LB 
formation in the absence of malin is still unresolved. 
Another unresolved point is the consequence of the laforin-malin mediated 
ubiquitination of substrates. Some reports indicate that ubiquitinated substrates are targeted 
for proteasomal degradation (e.g. laforin, R5/PTG, and glycogen synthase). However, 
ubiquitination of other substrates does not target them for proteasomal degradation (e.g. -
subunit of the AMPK complex). How can one reconcile these results? One possibility is 
that the laforin-malin complex introduces different ubiquitin chains depending on the E2 
that assists in substrate ubiquitination. This mechanism would explain why in some cases 
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the result of the action of the laforin-malin complex is the degradation of the substrate 
whereas in other cases the substrate is not degraded. Recent reports indicate that the laforin-
malin complex has a positive role in autophagy. As it has been reported that autophagy 
mediates the degradation of proteins that are labelled with K63-linked ubiquitin chains, it 
could be possible that the modification mediated by the laforin-malin complex would target 
substrates to be degraded by the lysosome. 
 Over the past decade, our understanding of Lafora disease has proceeded very 
rapidly. The latest results suggest that protein clearance may be a key pathway defective in 
LD. For this reason, LD may be considered as a novel member of protein clearance 
diseases (i.e., Parkinson’s, Alzheimer’s, and Huntington’s.) in addition to being a glycogen 
metabolism disease. If results concerning the mechanism of LD continue at their current 
pace, then our understanding of the molecular basis of this pathology will soon allow a 
rational therapeutic approach for this devastating disease. 
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FIGURE LEGENDS 
 
Fig. 1: A) Schematic depicting of the domains present in malin, numbering refers to human 
malin. The most frequent Lafora disease mutation observed in EPM2B-LD patients encodes 
malin-P69A. The malin-D146N mutation is involved in binding to laforin. B) RING and 
NHL-containing domains (amino acids 26-72 and 113-393, respectively) were submitted to 
the ESyPred3D server and modeled using the structure of human TRIM32 RING motif 
(PDB:2ct2) (RING model) and M. tuberculosis PknD (PDB:1rwl) (NHL model) as 
templates. Structural models were displayed using PyMOL. The position of critical residues 
of the zinc finger C3HC4 type in the RING domain are indicated in red; spheres represent 
zinc atoms; the position of the P69A mutation is also depicted. The six NHL domains are 
predicted to fold into a -propeller structure; the position of the D146N mutation, which 
affects the malin-laforin interaction, is also indicated. 
 
Fig. 2: Schematic summarizing the action of malin on different proteins and in different 
pathways. See text for details. 
 
Fig. 3: A) Proposed mechanism of action for malin in glycogen metabolism. The protein 
targeting to glycogen (PTG) subunit of PP1 and glycogen synthase (GS) both bind 
glycogen particles during normal glycogen metabolism. During glycogen synthesis, GS 
incorporates a phosphate (P) in glycogen on approximately 1/10,000 glucose monomers. 
Laforin is targeted to the glycogen particle via its CBM and liberates phosphate from 
glycogen. The malin-laforin interaction is enhanced by laforin-Ser25 phosphorylation via 
AMP-activated protein kinase. Once bound to laforin, malin ubiquitinates laforin, PTG, and 
GS. This ubiquitination triggers the release of all three enzymes from the glycogen particle, 
targets them for proteasome-dependent degradation, and allows glycogen metabolism to 
proceed normally. GS, glycogen synthase; P, phosphate group; PTG/R5, protein targeting 
to glycogen subunit of protein phosphatase 1; ub, ubiquitin. B) Predicted mechanisms that 
result in increased levels of glycogen synthase, PTG, and/or laforin in Epm2b-deficient 
mice. 
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